Open Medscience

JANUARY 1, 2024

Zirconium radiopharmaceuticals enhance nuclear medicine with precise diagnostics and potential therapeutic applications. The post Zirconium Radiopharmaceuticals in Nuclear Medicine appeared first on Open Medscience.

Nuclear Medicine 59

Nuclear Medicine Radiopharmaceuticals Diagnostic Medical 59

Open Medscience

DECEMBER 31, 2023

Lutetium radiopharmaceuticals significantly advance targeted cancer treatment and diagnostic capabilities. The post Lutetium Radiopharmaceuticals in Medicine: A Comprehensive Review appeared first on Open Medscience.

Radiopharmaceuticals 59

Radiopharmaceuticals Diagnostic Medical Imaging 59

Open Medscience

NOVEMBER 11, 2023

Copper radiopharmaceuticals offer groundbreaking diagnostic and therapeutic applications, revolutionising nuclear medicine, particularly in oncology and cardiology. The post Exploring Copper Radiopharmaceuticals: Innovations and Applications in Nuclear Medicine appeared first on Open Medscience.

Nuclear Medicine 59

Nuclear Medicine Radiopharmaceuticals Diagnostic Medical 59

Imaging Technology

DECEMBER 6, 2023

and Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today provided additional information regarding a March 2022 licensing and collaboration agreement between Philochem and Blue Earth Diagnostics.

Diagnostic 97

Diagnostic Diagnostic Imaging Clinic Radiopharmaceuticals 97

Imaging Technology

JANUARY 5, 2024

The PSMA Alpha-PET DoubLET platform technology represents a potential leap forward in the field of prostate cancer diagnostics and treatment. We focused on diagnostic accuracy, patient tolerance and convenience. It can also be used for beta-particle targeted RPT using copper isotopes.

Radiopharmaceuticals 79

Radiopharmaceuticals Clinic Nuclear Medicine Radiation 79

Imaging Technology

APRIL 5, 2024

milla1cf Fri, 04/05/2024 - 11:31 April 5, 2024 — RLS Radiopharmacies , America’s only Joint Commission-accredited radiopharmacy network, today announced it has expanded its radiopharmaceutical contract development and manufacturing (rCDMO) capabilities by entering into a strategic agreement with global isotope technology leader Eckert & Ziegler.

Radiopharmaceuticals 52

Radiopharmaceuticals Radiation Oncology Radiation Quality and Compliance 52

AuntMinnie

JULY 10, 2024

Centers for Medicare and Medicaid Services (CMS) proposed a new reimbursement plan July 10 for diagnostic PET scans that would provide separate payments for radiopharmaceuticals, as well as an extra payment for hospitals when they use domestically produced technetium-99m (Tc-99m).

Medicare 52

Medicare Nuclear Medicine Radiopharmaceuticals Imaging 52

Imaging Technology

SEPTEMBER 20, 2023

a therapeutic oncology company and 3B Pharmaceuticals (3BP) GmbH, a biotechnology company developing targeted radiopharmaceutical drugs and diagnostics for cancer detection and treatment, announced an exclusive licensing agreement for RefleXion to develop and commercialize a specific 3BP molecule to direct its SCINTIX biology-guided radiotherapy.

Pharmaceutical 97

Pharmaceutical Radiopharmaceuticals Radiation Diagnostic 97

Imaging Technology

JUNE 15, 2023

The clinical trial will use this investigational radiopharmaceutical to help understand if patients have CD8+ T cells in their tumors and will, therefore, be more likely to respond to immune checkpoint inhibitors, the main class of immunotherapies currently approved for use.

Radiopharmaceuticals 87

Radiopharmaceuticals Pharmaceutical Nuclear Medicine PET Scan 87

Diagnostic Imaging

JUNE 28, 2023

In a recent interview at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference in Chicago, Phillip Kuo, M.D.,

Radiopharmaceuticals 58

Radiopharmaceuticals Nuclear Medicine Imaging 58

Imaging Technology

JULY 5, 2024

68Ga-DOTA-RM2 will be used as a companion diagnostic. While new PSMA-targeted diagnostics and therapeutics are transforming prostate cancer care, there are many patients for whom PSMA-targeted therapy may not be appropriate,” said Brian Markison, Lantheus CEO. For more information: www.lantheus.com Friday, July 5, 2024 - 06:00

Diagnostic 89

Diagnostic Radiopharmaceuticals Disease IT 89

AuntMinnie

APRIL 4, 2024

Life Molecular Imaging (LMI) and Sofie Biosciences have begun offering the Neuraceq ( florbetaben F-18) PET radiotracer produced at Sofie's radiopharmaceutical manufacturing site in Cleveland, Ohio. With this expansion, LMI continues driving commercial sales of Neuraceq around the U.S.

Radiopharmaceuticals 95

Radiopharmaceuticals Imaging Disease Diagnostic 95

AuntMinnie

JULY 12, 2024

As nuclear medicine therapies gain stature compared to nuclear medicine in diagnostic imaging, hospital administrators may be eyeing the potential of adding theranostics services. Image courtesy of Washington University. "We Nuclear Regulatory Commission and is an integral part of a theranostics practice.

Nuclear Medicine 105

Nuclear Medicine Radiation Oncology Radiopharmaceuticals Radiation 105

Imaging Technology

JANUARY 5, 2024

milla1cf Fri, 01/05/2024 - 11:32 January 5, 2024 — NorthStar Medical Radioisotopes, LLC , a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, and Curadh MTR Inc. Chief Executive Officer of NorthStar Medical Radioisotopes.

Radiopharmaceuticals 52

Radiopharmaceuticals Medical Nuclear Medicine Pharmaceutical 52

Open Medscience

JUNE 22, 2024

Radiotheranostics combines diagnostic imaging and targeted radiotherapy, using radiopharmaceuticals for personalised, precise cancer treatment and improved outcomes. The post What is Radiotheranostics? The Future of Personalised Cancer Diagnosis appeared first on Open MedScience.

Radiopharmaceuticals 52

Radiopharmaceuticals Diagnostic Imaging Diagnostic Imaging 52

Diagnostic Imaging

JUNE 9, 2024

shared her perspective on a number of topics affecting nuclear medicine, ranging from isotope availability and reimbursement challenges for diagnostic radiopharmaceuticals to increasing patient interest in PET imaging. In a recent interview, Cathy Cutler, Ph.D.,

Nuclear Medicine 64

Nuclear Medicine Radiopharmaceuticals Diagnostic Imaging 64

Imaging Technology

MAY 30, 2023

milla1cf Tue, 05/30/2023 - 19:49 May 30, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals , today announced U.S. Chief Executive Officer of Blue Earth Diagnostics. Gauden , D.Phil.,

Diagnostic 75

Diagnostic Imaging Radiopharmaceuticals Diagnostic Imaging 75

Open Medscience

JUNE 22, 2024

Radiotheranostic Pairs combine diagnostic imaging with targeted radiotherapy, revolutionising personalised cancer treatment through enhanced precision and efficacy. The post Radiotheranostic Pairs: Bridging Diagnostics and Therapeutics in Cancer appeared first on Open MedScience.

Diagnostic 52

Diagnostic Diagnostic Imaging Imaging Radiopharmaceuticals 52

Imaging Technology

JUNE 21, 2023

POSLUMA (formerly referred to as to as 18F-rhPSMA-7.3 ) is an optimized, high-affinity radiohybrid (rh) Prostate-Specific Membrane Antigen (PSMA)-targeted PET imaging agent. Chief Executive Officer of Blue Earth Diagnostics Ltd. Blue Earth Diagnostics is at Booth 6025 and PETNET Solutions is at Booth 6075. Gauden , D.Phil.,

Diagnostic 75

Diagnostic Radiopharmaceuticals Imaging Medicare 75

Open Medscience

JANUARY 11, 2024

Theranostics merges diagnostics and therapy, revolutionising personalised medicine with genetic profiling and targeted treatment strategies. The post Theranostics Bridging Diagnostics and Therapy for Targeted Treatment appeared first on Open Medscience.

Diagnostic 115

Diagnostic Radiopharmaceuticals Medical Imaging 115

Imaging Technology

JUNE 10, 2024

The award was announced by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) during its 2024 Annual Meeting, June 8-11 in Toronto. More recently, she and her collaborators developed a PET imaging agent for vaso-occlusive crisis in sickle cell disease, recently approved for human studies by the FDA as an Investigational New Drug.

Nuclear Medicine 82

Nuclear Medicine Radiopharmaceuticals Disease Imaging 82

Imaging Technology

SEPTEMBER 27, 2023

PET imaging with POSLUMA reveals clinical information crucial to decision-making for men with prostate cancer, and we are excited to share further information with the radiation oncology community at ASTRO 2023,” said David E. Chief Executive Officer of Blue Earth Diagnostics. from October 1 to 4, 2023. Gauden , D.Phil., Kuo, MD, Ph.D.,

Diagnostic 93

Diagnostic Radiation Oncology Radiation Clinic 93

AuntMinnie

MAY 30, 2023

Food and Drug Administration (FDA) has approved Blue Earth Diagnostics. Read more on AuntMinnie.com Related Reading: Blue Earth touts clinical results Blue Earth highlights results from PET tracer trial PET tracer shows promise in imaging of brain tumors Blue Earth touts PSMA radiotracer study Blue Earth moves toward U.K.

Radiopharmaceuticals 52

Radiopharmaceuticals Imaging Diagnostic Clinic 52

Imaging Technology

JULY 28, 2023

It is the first and only FDA-approved, PSMA-targeted imaging agent developed with proprietary radiohybrid (rh) technology. POSLUMA is widely available through 36 radiopharmacies in the national network of Blue Earth Diagnostics’ commercial U.S. Chief Medical Officer of Blue Earth Diagnostics. manufacturer and distributor. “The

Clinic 85

Clinic Diagnostic Radiopharmaceuticals Radiation 85

Imaging Technology

JUNE 12, 2024

milla1cf Wed, 06/12/2024 - 21:58 June 12, 2024 — Cathy Sue Cutler, PhD, FSNMMI , chair of the Isotope Research and Production Department at Brookhaven National Laboratory in Upton, New York, has been named as president for the Society of Nuclear Medicine and Molecular Imaging (SNMMI).

Nuclear Medicine 107

Nuclear Medicine Radiopharmaceuticals Education Government 107

Diagnostic Imaging

JANUARY 12, 2024

The FDA has accepted Lantheus' abbreviated new drug application for a generic Lutathera, just months after Novartis announced positive phase 3 data supporting a first-line indication for the radiopharmaceutical in neuroendocrine tumors.

Radiopharmaceuticals 120

Radiopharmaceuticals 120

TTG Imaging Solutions

FEBRUARY 17, 2022

Imaging Conference & Expo: February 20 – 22, 2022 TTG Imaging Solutions will be exhibiting at the Imaging Conference & Expo in Napa, CA. For the latest updates on TTG Imaging Solutions, connect with us on LinkedIn , Twitter , and Facebook. Learn more about TTG in our video overview.

Nuclear Medicine 52

Nuclear Medicine Imaging Radiopharmaceuticals Diagnostic Imaging 52

Open Medscience

AUGUST 8, 2019

Imaging agents can be used to evaluate organ function, detect cancer, measure blood flow and follow metabolic processes. The post Radiometals for diagnostic imaging and theranostics appeared first on Open Medscience.

Diagnostic Imaging 52

Diagnostic Imaging Diagnostic Imaging Radiopharmaceuticals 52

TTG Imaging Solutions

MAY 5, 2023

Enhances TTG’s continued commitment to offer a full spectrum of high-quality and cost-effective service solutions in the cardiology and radiation oncology markets PITTSBURGH, PA (May 5, 2023) – TTG Imaging Solutions, LLC (TTG) announced today the acquisition of Digirad Health, Inc., headquartered in Suwanee, GA. Digirad Health, Inc.

Imaging 52

Imaging Radiopharmaceuticals Radiation Oncology Nuclear Medicine 52

AuntMinnie

JUNE 20, 2024

F-18 fluorocholine (FCH) PET/CT could be a first-line technique over technetium-99m sestamibi (Tc-99m MIBI) SPECT/CT for imaging parathyroid tumors prior to surgery, according to a study published June 20 in JAMA Otolaryngology-Head & Neck Surgery. No complications occurred. The full study is available here.

Radiopharmaceuticals 105

Radiopharmaceuticals Radiation Imaging Clinic 105

AuntMinnie

JUNE 27, 2023

Blue Earth Diagnostics, a Bracco company, is highlighting results from a stud. Read more on AuntMinnie.com Related Reading: FDA approves new PET tracer for prostate cancer imaging Blue Earth touts clinical results PET tracer shows promise in imaging of brain tumors Blue Earth touts PSMA radiotracer study Blue Earth moves toward U.K.

Radiopharmaceuticals 52

Radiopharmaceuticals Diagnostic Clinic Imaging 52

AuntMinnie

MAY 17, 2023

The Facilitating Access to Innovative Diagnostics (FIND) Act -- legislatio. Read more on AuntMinnie.com Related Reading: FIND Act reintroduced in Congress MITA hails radiopharmaceutical legislation SNMMI supports new legislation to fix PET payment policy Molecular imaging saw wins, losses over past year

Radiopharmaceuticals 52

Radiopharmaceuticals Diagnostic Imaging 52

Open Medscience

NOVEMBER 9, 2023

The post Unveiling the Complex Etiology and Innovative Diagnostic Approaches in Alzheimer’s Disease appeared first on Open Medscience. Alzheimer's disease stems from genetic mutations and lifestyle factors, leading to brain plaque accumulation and dementia.

Disease 59

Disease Diagnostic Nuclear Medicine Radiopharmaceuticals 59

TTG Imaging Solutions

OCTOBER 20, 2021

The American Society for Radiation Oncology 2021 Annual Meeting: October 24 – 26 TTG Imaging Solutions is proud to be exhibiting at the American Society for Radiation Oncology Annual Meeting in Chicago, IL. For the latest updates on TTG Imaging Solutions, connect with us on LinkedIn , Twitter , and Facebook.

Radiation Oncology 52

Radiation Oncology Imaging Radiopharmaceuticals Radiation 52

TTG Imaging Solutions

JANUARY 9, 2022

The American Society of Nuclear Cardiology Cardiac PET Intensive Virtual Workshop: Jan 14 – 16, 2022 TTG Imaging Solutions is proud to sponsor the American Society of Nuclear Cardiology Cardiac PET Intensive Virtual Workshop. For the latest updates on TTG Imaging Solutions, connect with us on LinkedIn , Twitter , and Facebook.

Nuclear Medicine 52

Nuclear Medicine Imaging Radiopharmaceuticals Diagnostic Imaging 52

TTG Imaging Solutions

SEPTEMBER 28, 2021

The American Society of Nuclear Cardiology 2021 Virtual Annual Meeting: September 30 – October 2 TTG Imaging Solutions is proud to be a Bronze Sponsor at the American Society of Nuclear Cardiology Virtual Annual Meeting. For the latest updates on TTG Imaging Solutions, connect with us on LinkedIn , Twitter , and Facebook.

Nuclear Medicine 52

Nuclear Medicine Imaging Radiopharmaceuticals Diagnostic Imaging 52

Open Medscience

MAY 14, 2024

Positron Emission Tomography Imaging has advanced with cutting-edge technologies, enhancing diagnostic accuracy and expanding clinical applications dramatically. The post Breakthroughs in Positron Emission Tomography Imaging appeared first on Open MedScience.

Imaging 52

Imaging Diagnostic Clinic Nuclear Medicine 52